1 research outputs found
NEWLY DIAGNOSED NEOPLASIA IN CROHN DISESE PATIENTS TREATED WITH INFLIXIMAB;A 1 YEAR LONGER FOLLOW UP FROM A MULTICENTER MATCHED PAIR STUDY
1. Inflamm Bowel Dis. 2011 Mar;17(3):758-66. doi: 10.1002/ibd.21416.
Cancer in Crohn's Disease patients treated with infliximab: a long-term
multicenter matched pair study.
Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci
E, Castiglione F, D'Incà R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G,
Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F.
GI Unit, University, Tor Vergata, Roma. [email protected]
BACKGROUND: The long-term risk of neoplasia in Crohn's disease (CD) patients
treated with infliximab is undefined. The aim was to assess, in a multicenter,
matched-pair study, whether infliximab use in CD is associated with an increased
frequency of neoplasia in the long term.
METHODS: A multicenter, long-term, matched-pair study was conducted in 12
referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD
patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls
never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up
for an additional 4 years (2004-2008). Cases and controls were matched for: sex,
age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CD
duration (±5 years). From 1999 to 2008 the frequency and characteristics of
neoplasia were compared between CD-IFX and CD-C.
RESULTS: In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched
couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months:
72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency of
neoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94%)
and CD-C (12/287; 4.19%; P = 0.95). A comparable frequency of neoplasia was also
observed between the 221 matched couples (CD-IFX: 8/221; 3.61% versus CD-C:
9/221; 4.07%; P = 1). No specific histotype of cancer appeared associated with
infliximab use.
CONCLUSIONS: The frequency of neoplasia was comparable in an adult population of
CD patients treated or not with infliximab, matched for clinical variables and
followed up for a median of 6 years.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
PMID: 20684009 [PubMed - indexed for MEDLINE